Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody

Yoshihiro Ohue1, Koji Kurose1, Yu Mizote1, Hirofumi Matsumoto1, Yumi Nishio1, Midori Isobe1, Minoru Fukuda2, Akiko Uenaka3, Mikio Oka1, and Eiichi Nakayama3

Abstract

Purpose: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarcinoma.

Experimental Design: The XAGE1 (GAGED2a) antigen expression and EGFR mutation were determined with tumor tissues. The XAGE1 (GAGED2a) antibody and T-cell immune responses, as well as immune cell phenotypes, were analyzed with blood samples. Patients with EGFR wild-type (EGFRwt) tumors were treated with conventional platinum-based doublet chemotherapy and patients with EGFR-mutated (EGFRmt) tumors were treated with EGFR-TKI and conventional chemotherapy. The overall survival (OS) rates of the antibody-positive and -negative patients were investigated.

Results: The results showed that the OS of antibody-positive patients was prolonged significantly compared with that of antibody-negative patients with either XAGE1 (GAGED2a) antigen-positive EGFRwt (31.5 vs. 15.6 months, \( P = 0.05 \)) or EGFRmt (34.7 vs. 11.1 months, \( P = 0.001 \)) tumors. Multivariate analysis showed that the presence of the XAGE1 (GAGED2a) antibody was a strong predictor for prolonged OS in patients with XAGE1 (GAGED2a) antigen-positive tumors and in patients with either EGFRwt or EGFRmt tumors. On the other hand, XAGE1 (GAGED2a) antigen expression was a worse predictor in patients with EGFRmt tumors. Phenotypic and functional analyses of T cells indicated immune activation in the antibody-positive patients.

Conclusions: The findings suggest that production of the XAGE1 (GAGED2a) antibody predicts good prognosis for patients with lung adenocarcinoma as an immune biomarker and the protective effect of this naturally occurring immune response supports the concept of immunotherapy.

Clin Cancer Res; 20(19); 5052–63. ©2014 AACR.

Introduction

Cancer/testis (CT) antigen is a class of antigens that express predominantly in the testes in normal adult tissues and in various tumors (1–3). The CT database (4) lists 276 CT antigen genes, including 128 genes on the X chromosome (CT-X), nine genes on the Y chromosome, and 139 genes on various autosomes (non-X CT). Some CT antigens have been shown to be highly immunogenic and are considered to be attractive targets for cancer vaccines (5–8).

XAGE1 was originally identified by the search for PAGE/GAGE-related genes using an expression sequence tag database (9) and was shown to exhibit CT antigen characteristics (10, 11). Five identical genes, XAGE1A to E, have been identified, being dispersed in a region of approximately 350 kilobases on chromosome Xp11.22 (12). The associated protein is designated as a G antigen family D member 2 (GAGED2), and GAGED2a and d isoforms have been identified (9, 12). Four transcript variants XAGE-1a, b, c, and d have been extensively studied and shown to be expressed in various tumors (13–16). The XAGE-1a and b transcripts code for 81 amino acid XAGE1 (GAGED2a) protein, whereas the XAGE-1d transcript codes for a 69 amino acid XAGE1 (GAGED2d) protein (17).

The XAGE1 (GAGED2a) antigen is expressed in approximately 40% of advanced lung adenocarcinomas (18–21). Approximately half of the patients with antigen-positive tumors naturally produced the XAGE1 (GAGED2a)
antibody (19, 21). A CD4 T-cell response was detected in 14 of 16 and a CD8 T-cell response in 6 of 9 XAGE1 (GAGED2a) antibody-positive patients examined in our previous study (21). Frequent antibody and CD4 and CD8 T-cell responses indicate the strong immunogenicity of the XAGE1 (GAGED2a) antigen.

In this study, we investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarcinoma. A recent comprehensive analysis of human gene expression has identified the Igκ constant (IGKC) gene as a strong prognostic marker in human solid tumors, including lung cancer (22). Identification of tumor-infiltrating plasma cells as the source of IGKC expression strongly suggests a role in immune responses and provides a compelling rationale for investigating the relation of humoral immune responses against lung cancer antigens and prognosis.

Patients with EGFR wild-type (EGFRwt) tumors were treated with conventional platinum-based doublet chemotherapy and patients with EGFR-mutated (EGFRmt) tumors were treated with EGFR tyrosine-kinase-inhibitor (EGFR-TKI) as first-line chemotherapy until progression or intolerable adverse effects following conventional chemotherapy. Patients with EGFRmt tumors were treated with an EGFR tyrosine-kinase-inhibitor (EGFR-TKI) as first-line chemotherapy until progression or intolerable adverse effects following conventional platinum-based doublet chemotherapy. Patients were observed prospectively until death, loss of follow-up, or withdrawal of consent. Patient characteristics are shown in Supplementary Table S1A.

Overlapping peptides


Synthetic XAGE1 (GAGED2a) protein

XAGE1 (GAGED2a) protein (81 amino acids) was synthesized using a peptide synthesizer by GL Biochemistry.

Reverse transcription PCR

Total RNA was obtained from cells using an RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. Two micrograms of each sample were subjected to cDNA synthesis using a Ready-To-Go first strand beads kit (GE Healthcare). Sequences of primer pairs for XAGE1 (transcript variant b) were X-1, 5ʹ-

---

Translational Relevance

XAGE1 (GAGED2a) is a cancer/testis (CT) antigen expressed frequently in lung adenocarcinomas. The findings indicated that the XAGE1 (GAGED2a) immune response is relevant for better prognosis in patients with advanced lung adenocarcinomas and that the XAGE1 (GAGED2a) antibody response is a prognostic biomarker. On the other hand, XAGE1 (GAGED2a) antigen expression is predictive of a worse prognosis in patients with EGFR-mutated tumors.
TTTCTCCGCTACTGAGACAC-3' and X-2, 5'-CAGCTTGC-GTTGTTCCACCTGC-TA-3'.

The amplification was performed using 30 cycles as described (19).

Thirteen of 145 specimens were examined by both IHC and reverse transcription PCR (RT-PCR). The numbers of RT-PCR–positive and –negative specimens were 3 and 10, respectively. Two of three positive specimens were also positive for IHC, but one was negative. All 10 negative specimens were negative for IHC.

**EGFR mutation**

EGFR mutations were examined by a PNA-LNA PCR clamp using paraffin-embedded tissue samples in Mitsu-bishi Chemical Medicine.

**IHC**

IHC for XAGE1 (GAGED2a) antigen expression was done with transbronchial or CT-guided lung biopsy specimens from all 145 patients and for additional pleural effusion cells from 22 patients. Tumor biopsy specimens or cells in pleural effusion were fixed with buffered formalin and embedded in paraffin. Five-micrometer sections were deparaffinized with xylene and ethanol. Antigen retrieval and inactivation of endogenous peroxidase were done as described previously (17, 19, 20). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19). After washing, the USO and inactivation of endogenous peroxidase were done as described (19).

**ELISA**

Synthetic XAGE1 (GAGED2a) protein (1 μg/mL) in a coating buffer was adsorbed onto a 96-well ELISA plate (Nunc) and incubated overnight at 4°C. Plates were washed with PBS and blocked with 5% FCS/PBS (200 μL/well) for 1 hour at 37°C. After washing, 100 μL of serially diluted serum was added to each well and incubated for 2 hours at 4°C. After washing, each horseradish peroxidase-conjugated goat anti-human IgG (MBL), IgG1 (Southern Biotechnology Associates), IgG2 (Southern Biotechnology Associates), IgG3 (Southern Biotechnology Associates), and IgG4 (Southern Biotechnology Associates) were added to the wells, and the plates were incubated for 1 hour at 37°C. After washing and development, absorbance was read at 490 nm.

**Flow cytometry**

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by density gradient centrifugation using a Histopaque 1077 (Sigma-Aldrich). CD4 and CD8 cells were purified by magnetic cell sorting (Miltenyi Biotec). The residual cells were kept for use as antigen-presenting cells (APC). The cells were stored in liquid N2 until use. After thawing, PBMCs were incubated with the monoclonal antibodies for 20 minutes at 4°C.

**Foxp3 staining**

Intracellular Foxp3 staining was performed using a Foxp3 staining buffer set (eBioscience) according to the manufacturer’s instructions. Anti-CD4-V500 (BD Horizon), anti-CD8-APC/Cy7 (BD Pharmingen), and anti-CD278 (OX40)-PerCP/Cy5.5 (clone G025H7; BD Bioscience) were used for analysis of activation and inhibitory molecules on T cells. After incubation, the cells were washed and analyzed by FACS Canto II (BD Bioscience).

**In vitro stimulation of CD4 and CD8 T cells with the XAGE1 (GAGED2a) antigen and detection of cytokine production**

CD4 (1 × 10^6/well) and CD8 (1 × 10^6/well) T cells were cultured with an equal number of irradiated (40 Gy) autologous CD4- and CD8-depleted cells as APC in the presence of a mixture of 17 16-mer overlapping peptides (10^{-6} mol/L) for CD4 T cells and in the presence of synthetic XAGE1 (GAGED2a) protein (10^{-6} mol/L) for CD8 T cells on a 48-well culture plate (BD Bioscience) for 12 days at 37°C in a 5% CO2 atmosphere. The medium was AIM-V (Invitrogen) supplemented with 5% heat-inactivated pooled human serum, 2 mmol/L L-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin, 10 U/mL recombinant IL2 (Takeda Chemical Industries), and 10 ng/mL recombinant IL7 (Peprotech).
After incubation, responder CD4 or CD8 T cells (1 × 10^5) harvested from the stimulation culture were washed and then pulsed with 17 16-mer OLPs for CD4 T cells or 35 12-mer OLPs for CD8 T cells with GolgiStop monensin (Sigma Chemical Co.) for 3 hours. After incubation, cytokine production by CD4 and CD8 T cells was detected by intracellular cytokine staining (ICS).

Intracellular cytokine staining

The cells harvested from culture were washed and stained with anti-CD3-PerCP/Cy5.5 (clone SK7; eBioscience) and anti-CD4-V500 (clone HIT3a; BioLegend), anti-CD8-V500 (clone RPA-T8; BD Horizon), and anti-CD107a-FITC (clone H4A3; BD Pharmingen; 2 μl) for 30 minutes on ice. After incubation, the cells were washed, fixed, and permeabilized with Cytofix/Cytoperm solution (Pharmingen, Becton Dickinson) for 20 minutes at 4°C. Then, the cells were washed in Perm/Wash solution (Pharmingen), and pelleted cells were stained for intracellular cytokines using anti-IFNγ-PerCP/Cy7 (clone 4S.B3; eBioscience), anti-TNFα-PerCP/Cy7 (clone MAb11; eBioscience), anti-IL-17A-Brilliant Violet 421 (clone BL168; BioLegend), anti-IL-17F-Brilliant Violet 421 (clone O33-782; BD Pharmingen), and anti-IL-10-APC (clone JES3-19F1; BioLegend) for detection of CD4 cytokines or anti-IFNγ-PerCP/Cy5.5 (clone 4S.B3; eBioscience), anti-TNFα-Brilliant Violet 421 (clone MAb11; BioLegend), and anti-IL-10-APC (clone JES3-19F1; BioLegend) for detection of CD8 cytokines for 30 minutes on ice. After incubation, the cells were washed and analyzed by FACS Canto II (BD Bioscience). The data were analyzed using FlowJo software (version 7.6.5; Tree Star). If the number of cytokine-staining cells stimulated with XAGE1 (GAGED2a) OLPs was more than 2-fold the number of staining cells stimulated with control peptides, it was defined as positive (23).

Overall survival

The diagnosis of lung cancer was done pathologically within a month after the first visit. OS was measured from the day of diagnosis and analyzed by the Kaplan–Meier method. Differences in survival between patient subgroups were analyzed using the log-rank test. Univariate and multivariate analyses using Cox proportional hazards regression model were performed to assess the association of each factor with OS. P values less than 0.05 were considered significant.

Statistical analysis

Statistical analysis was performed with the Student t test for two groups and with ANOVA for multiple groups using IBM SPSS Statistics 19 for Windows (IBM). Quantitative data without a normal distribution were analyzed with nonparametric tests, and data with a normal distribution were analyzed with parametric tests. For a two-sample comparison of continuous variables, Wilcoxon rank-sum test was performed. For analysis of the correlation of the extrapolated titer and each parameter, Pearson rank test was performed. Results are expressed as the mean or 95% confidence interval (95% CI).

Results

XAGE1 (GAGED2a) antibody response in patients with advanced lung adenocarcinoma

Characteristics of 145 patients with advanced (clinical stage IIIIB and IV) lung adenocarcinoma investigated in this study are shown in Supplementary Table S1A. We evaluated the serum IgG response against XAGE1 (GAGED2a) in the patients by ELISA using a synthetic protein. An extrapolated titer was calculated for each serially diluted serum sample as described (24). The IgG response was defined as positive for sera with extrapolated titers exceeding or equal to 100. Thirty-three patients were antibody positive and titration curves of sera are shown in Fig. 1A. The dominant IgG subtypes were IgG1 and IgG3, and no IgG2 or IgG4 response was observed (Fig. 1B). The positive response was further classified by extrapolated titers as ++ + (≥ 6,400), ++ (1,600 < + + ≤ 6,400), + (1,600 > ++ ≥ 400), and + (400 > weak + ≥ 100 (Fig. 1C).

A higher antibody response frequency was observed in patients with EGFRmt tumors than in patients with EGFRwt tumors of the 145 patients (Supplementary Table S1A). However, no significant difference was observed for the antibody response in any characteristics in 58 patients with XAGE1 (GAGED2a) antigen-positive tumors (data not shown).

Detection of CD4 and CD8 T-cell responses in PBMCs from XAGE1 (GAGED2a) antibody-positive advanced lung adenocarcinoma patients

Purified CD4 and CD8 T cells in PBMCs from XAGE1 (GAGED2a) antibody-positive advanced lung adenocarcinoma patients were stimulated for 12 days with CD4- and CD8-depleted PBMCs treated with XAGE1 (GAGED2a) 17 16-mer OLPs or a synthetic protein, respectively. After culture, the cells were collected and cytokine production was examined for CD4 T cells after 3-hour stimulation with XAGE1 (GAGED2a) 17 16-mer OLPs and for CD8 T cells after 3-hour stimulation with XAGE1 (GAGED2a) 35 12-mer OLPs by ICS. As shown in Fig. 1D and Supplementary Fig. S1, IFNγ/TNFα, IL5/IL13, and IL17A/IL17F-producing CD4 T cells were detected in PBMCs from 7, 1, and 3 of 11 patients examined, respectively. IL10-producing CD4 T cells were not detected in any of the patients. On the other hand, IFNγ- and TNFα-producing CD8 T cells were detected in PBMCs from 4 and 6 of 11 patients, respectively. IL10-producing CD8 T cells were not detected in any. No XAGE1 (GAGED2a) antibody responses or CD4 or CD8 T-cell responses were detected in healthy individuals as reported previously (21).

Statistical analysis with parametric tests. For a two-sample comparison of continuous variables, Wilcoxon rank-sum test was performed. For analysis of the correlation of the extrapolated titer and each parameter, Pearson rank test was performed. Results are expressed as the mean or 95% confidence interval (95% CI).

Phenotypic analyses of CD4 T cells and MDSCs in PBMCs from XAGE1 (GAGED2a) antibody-positive patients

Th1, Th2, Th17, and Treg CD4 T cells, resting and activated CD4 Tregs (25), and M- and PMN-MDSCs in PBMCs from XAGE1 (GAGED2a) antibody-positive patients were analyzed by flow cytometry (Supplementary Fig. S2). As...
shown in Fig. 2A, all Th1, Th2, Th17, and T_{FH} CD4 T-cell levels were elevated in XAGE1 (GAGED2a) antibody-positive patients compared with those in antibody-negative patients. A decrease in activated, but not resting, Treg levels was also observed (Fig. 2B). Furthermore, a decrease in the M-MDSC level and an increase in the PMN-MDSC level were observed (Fig. 2C). Th1, Th2, and Th17/total Treg and Th1, Th2, and Th17/total MDSC levels were increased (Fig. 2D and E). An increase in T_{FH}/total MDSC, but not the T_{FH}/Treg level, was observed (Fig. 2D and E).

Analysis of CD4 and CD8 T cells expressing T-cell activation and inhibitory molecules in PBMCs from XAGE1 (GAGED2a) antibody-positive patients

CD4 and CD8 T cells expressing T-cell activation molecules ICOS, OX40, 4-1BB, and GITR, and T-cell inhibitory
molecules 2B4, BTLA, PD-1, and Tim-3 in PBMCs from XAGE1 (GAGED2a) antibody-positive patients were investigated. As shown in Fig. 3 and Supplementary Fig. S3, an increase in ICOS and PD-1–positive cell levels and a decrease in BTLA-positive cell levels were observed in CD4 T cells from antibody-positive patients compared with those in CD4 T cells from antibody-negative patients. On the other hand, a decrease in GITR-positive cell levels was observed in CD8 T cells from antibody-positive patients.

Overall survival of XAGE1 (GAGED2a) antibody-positive and -negative patients

The OS of XAGE1 (GAGED2a) antibody-positive and -negative patients was analyzed for 145 patients with advanced lung adenocarcinoma. Patient characteristics are shown in Supplementary Table S1A, as described above.

OS was first analyzed for the patients with XAGE1 (GAGED2a) antigen-positive and -negative tumors. As shown in Fig. 4A, no significant difference was found in OS between them ($P = 0.22$, HR, 0.78). However, prolongation of OS was observed in XAGE1 (GAGED2a) antibody-positive patients compared with antibody-negative patients ($P = 0.006$, HR, 0.53; Fig. 4B). The median OS times in the antibody-positive and -negative patients were 33.3 months and 15.1 months, respectively. Antibody-negative patients were then stratified by the XAGE1 (GAGED2a) antigen expression in the tumor. As shown in Fig. 4C, the antibody-negative patients with antigen-positive tumors showed shortened survival. The median

Figure 2. Phenotypic analyses of CD4 T cells (A and B) and MDSCs (C) in PBMCs from 23 XAGE1 (GAGED2a) antibody-positive and 12 negative patients, and 5 healthy donors by FACS. D and E show the ratio of each phenotype of T cells to Tregs and MDSCs, respectively. Statistical analysis was done by the Student $t$ test for two groups and by ANOVA for multiple groups ($*, P < 0.05; **, P < 0.01; ***$, $P < 0.001; ****$, $P < 0.0001$). Each dot indicates a single patient.
OS in the patients with antigen-positive tumors was 33.3 months when antibody-positive, but only 13.7 months when antibody-negative (P < 0.0001, HR, 0.34). Furthermore, prolongation of OS was dependent on the IgG titer (Supplementary Fig. S4).

The patients were further stratified by the absence or presence of the EGFR mutation in the tumor. The patients with EGFRmt tumors treated with EGFR-TKI and conventional platinum-based doublet chemotherapy showed prolonged OS compared with the patients with EGFRwt tumors treated with conventional chemotherapy alone (P = 0.017; Fig. 5A and C and Supplementary Fig. S5A). OS was prolonged by the presence of antibodies in patients with XAGE1 (GAGED2a) antigen-positive EGFRwt or EGFRmt tumors (Fig. 5B and D). The median OS in the patients with XAGE1 (GAGED2a) antigen-positive EGFRwt tumors was 31.5 months when antibody-positive, but only 15.6 months when antibody-negative (P = 0.05, HR, 0.46; Fig. 5B). On the other hand, in the patients with XAGE1 (GAGED2a) antigen-positive EGFRmt tumors, the median OS was 34.7

---

**Figure 3.** Analysis of CD4 (A) and CD8 (B) T cells expressing T-cell activation (ICOS, OX40, 4-1BB, and GITR) and inhibitory (2B4, BTLA, PD-1, and Tim-3) molecules in PBMCs from XAGE1 (GAGED2a) antibody-positive and negative patients, and healthy donors by FACS. Statistical analysis was done by the Student t test for two groups and by ANOVA for multiple groups ( *, P < 0.05; **, P < 0.01; ***, P < 0.001). Each dot indicates a single patient.
months when antibody-positive, but only 11.1 months when antibody-negative \((P = 0.001, HR, 0.28; \text{Fig. 5D})\). No significant difference was found in OS in the antibody-positive patients with EGFRwt and EGFRmt tumors, or the patients with antigen-negative EGFRmt tumors \((P = 0.002, HR, 0.17; \text{Supplementary Table S2B})\). XAGE1 (GAGED2a) antigen expression was a worse predictor in 5 of 10 antibody-positive patients and sustained in 5 other patients. No positive conversion was observed in 3 antibody-negative patients. With 5 antibody response-augmented patients, various immune parameters were compared at diagnosis and at the late phase of disease progression. As shown in Fig. 6B, an increase in CXCR5- (Th1) CD4 T-cell level, but not CXCR3- (Th1) CD4 T-cell level, was observed. No change in resting or activated Treg level was observed \((\text{Fig. 6C})\). M- and PMN-MDSC levels were increased at the late phase \((\text{Fig. 6C})\). An increase in Tim-3 expression level was observed in CD8 T cells \((\text{Fig. 6D})\). Functional analysis showed that impaired XAGE1 (GAGED2a)-specific CD4 \((\text{Fig. 6E})\) and CD8 \((\text{Fig. 6F})\) T-cell responses for cytokine production were observed frequently at the late phase.

**Discussion**

In this study, we demonstrated that XAGE1 (GAGED2a) antibody-positive advanced lung adenocarcinoma patients showed prolonged OS when compared with the OS of antibody-negative patients. In patients with XAGE1 (GAGED2a) antigen-positive tumors, no significant difference was found in OS in patients with EGFRwt and EGFRmt tumors when they were XAGE1 (GAGED2a) antibody-positive \((\text{Fig. 5 and Supplementary Fig. S5})\). It should be noted that the patients with EGFRmt tumors treated with EGFR-TKI and conventional platinum-based doublet chemotherapy showed prolonged OS compared with those with EGFRwt tumors treated with conventional chemotherapy alone \((\text{Supplementary Fig. S5})\). The presence of the antibody greatly prolonged OS in patients with XAGE1 (GAGED2a) antigen-positive EGFRwt tumors, resulting in OS close to that of antibody-positive patients with EGFRmt tumors.

The patients with XAGE1 (GAGED2a) antigen-positive EGFRmt tumors showed shortened OS when the patients were antibody-negative compared with that of those with...
antigen-negative EGFRmt tumors. It should be noted that the survival shortening effect of XAGE1 (GAGED2a) antigen expression was observed only in patients with EGFRmt tumors, but not in those with EGFRwt tumors. These findings suggest specific involvement of the XAGE1 (GAGED2a) antigen in EGFRmt tumors or with EGFR-TKI treatment. The presence of the XAGE1 (GAGED2a) antigen in a tumor may facilitate EGFR-mediated tumorigenesis and/or hamper the effect of EGFR-TKI, and the presence of the XAGE1 (GAGED2a) antibody may inhibit this effect. EGFR signaling was delivered via the PI3K, AKT, and mTOR, or Ras, Raf, MEK, and MAPK pathways to activate many tumorigenic genes (26–30). These involve cell cycle, cell proliferation, antiapoptosis, invasion, or metastasis (31–33). Although the XAGE1 (GAGED2a) antigen has been shown to locate in the nucleus, the possibility of direct molecular interaction between XAGE1 (GAGED2a) and mutated EGFR, its downstream molecules, or EGFR-TKI itself remains to be addressed.

The function of the XAGE1 (GAGED2a) molecule is largely unknown. However, Caballero and colleagues (34) recently showed that XAGE1 depletion in an SK-MEL-37 melanoma cell line by siRNAs reduced proliferation, clonogenic survival, migration, and invasion of the cells. The tumorigenic effect of cancer/testis antigen on the X chromosome (CT-X) was also shown in SSX4 (34) and MAGE (35, 36). For XAGE-related GAGE genes, the proteins bind to the metazoan transcriptional regulator, germ cell-less (GCL), at the nuclear envelope and cause tumorigenesis (37). These findings suggest that the tumorigenic effect is a common characteristic of CT-X antigens.

CT-X expression has been shown to be a marker of poor outcome in non–small cell lung cancer (NSCLC) (38). The expressions of NY-ESO-1, MAGE-A1, MAGE-A3, and SSX2 were associated with shorter survival in lung adenocarcinoma. Especially, high-level expression of NY-ESO-1 or MAGE was a strong predictor for worse outcome independent of confounding factors such as stage, histology, and therapy. With XAGE1 (GAGED2a), no significant difference was observed in OS with the antigen-positive and negative-patients. Moreover, we previously reported that no correlation was found between the expression pattern (diffuse, intermediate, or focal) and OS (19). It is possible that the higher frequency of antibody response causing prolonged survival may obscure the difference.

The prolongation of OS by the presence of the XAGE1 (GAGED2a) antibody counteracting the survival shortening effect of XAGE1 (GAGED2a) antigen expression may not result from direct interaction of the antibody and antigen.

The XAGE1 (GAGED2a) antigen resides in the cells, usually in the nucleus as mentioned above. It is unlikely that the antibody enters the cell and interacts with XAGE1.
Rather, it is likely that T-cell responses elicited concomitantly with the antibody response contribute to the antitumor effect. Our previous (21) and present results showed frequent occurrence of CD4 and CD8 T-cell responses in XAGE1 (GAGED2a) antibody-positive patients and no such T-cell responses in antibody-negative patients. Thus, CD4 and CD8 T-cell responses seemed to be associated with the antibody response in patients with XAGE1 (GAGED2a)-positive tumors. In patients with NY-ESO-1–positive tumors, such a naturally occurring integrated immune response was frequently observed (39, 40). NY-ESO-1 is a prototype of the CT antigen and has been shown to be strongly antigenic (41). XAGE1 (GAGED2a) seemed to be less immunogenic than NY-ESO-1 (21), but still capable of eliciting an integrated immune response. In our previous study, we demonstrated that XAGE1 (GAGED2a) expression resulted in shorter survival in patients with NSCLC when the MHC class I expression was downregulated in the tumor (20). However, when the tumor coexpressed XAGE1 (GAGED2a) and MHC class I, survival was clearly prolonged. These findings suggest the involvement of CD8 T-cell activation in recognizing the XAGE1 (GAGED2a) antigen on HLA class I may contribute to prolonged survival.

On the other hand, recent exome analysis to determine mutations in the tumor has revealed the relevance of

Figure 6. Augmented or sustained antibody response, but increased immune inhibition, during the late phase of disease progression in XAGE1 (GAGED2a) antigen-positive, advanced lung adenocarcinoma patients. A, kinetic XAGE1 (GAGED2a) antibody response by ELISA during a prolonged period until death by disease progression in 10 XAGE1 (GAGED2a) antibody-positive (P01–P10, black lines) and 3 antibody-negative (P11–P13, red lines) patients. Five patients showing an increase in antibody titer are denoted by asterisks and were analyzed for CXCR3 and CXCR5-positive CD4 T cells (B), resting and activated Tregs, and M- and PMN-MDSCs (C), and Tim-3 expression in CD4 and CD8 T cells (D) at diagnosis or at the late phase by FACS. Statistical analysis was done by the Wilcoxon rank test (*, P < 0.05). Each line indicates a single patient. E and F show the responses of CD4 and CD8 T cells, respectively, against the XAGE1 (GAGED2a) antigen determined for cytokine production by ICS as described in the Fig. 1D legend. In F, the expression of the CD107a molecule on CD8 T cells was also analyzed by FACS.
immune responses to multiple mutated gene products in the tumor (42–45). Because XAGE1 (GAGED2a) expression is mostly heterogeneous, the immune response to XAGE1 (GAGED2a) could be a surrogate for such immune responses to mutated antigens.

In this study, we characterized various immune parameters in XAGE1 (GAGED2a)-antibody-positive patients and showed elevated immune responsiveness. XAGE1 (GAGED2a)-reactive CD4 and CD8 T cells were detected in the antibody-positive patients. Increases in Th1, 2, 17, Tfh levels and decreases in activated Treg and M-MDSC levels were observed in the antibody-positive patients. An increase in ICOS and PD-1–expressing CD4 T-cell levels and a decrease in BTLA-expressing CD4 T-cell levels were observed in the antibody-positive patients. These findings suggested that in XAGE1 (GAGED2a) antibody-positive patients, immune activation involving CD4 and CD8 T cells occurred in response to the XAGE1 (GAGED2a) antigen, supporting elicitation of an integrated immune response.

At the late phase of disease progression long after finishing treatment, the XAGE1 (GAGED2a) antibody response was still augmented or sustained. CXCR3+ (Th1) and CXCR5+ (Tfh) CD4 T-cell levels were retained or increased. However, increases in M- and PMN-MDSC, and Tim-3–expressing CD8 T-cell levels were observed. A reduction in XAGE1 (GAGED2a)-reactive CD4 and CD8 T-cell responses was frequently observed at the late phase. These findings suggest that immune regulation is one of the causes leading to disease progression resulting in death, even in patients with prolonged survival.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Y. Ohue, Y. Mizote, M. Oka, E. Nakayama
Development of methodology: Y. Ohue, Y. Mizote
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Ohue, Y. Mizote
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Ohue, Y. Mizote, M. Oka
Writing, review, and/or revision of the manuscript: Y. Ohue, M. Oka, E. Nakayama

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Ohue, H. Matsuimoto, Y. Nishio, M. Isobe, M. Fukuda, A. Uenaka, M. Oka

Study supervision: M. Oka, E. Nakayama

Acknowledgments
The authors thank Junko Mizuuchi for the preparation of the article.

Grant Support
This work was supported in part by a grant from Cancer Research Institute, N.Y., by JSPS KAKENHI (23291169 and 26830117), by grants from the Okayama Medical Foundation, by a grant from Kawasaki Medical School, and by a grant from Kawasaki University of Medical Welfare. This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), Ministry of Education, Culture, Sports, Science and Technology of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 26, 2014; revised June 26, 2014; accepted July 14, 2014; published OnlineFirst August 14, 2014.

References

5062 Clin Cancer Res; 20(19) October 1, 2014 Clinical Cancer Research
The XAGE1 Antibody as a Biomarker for Lung Cancer


Clinical Cancer Research

Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody

Yoshihiro Ohue, Koji Kurose, Yu Mizote, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-0742

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/08/16/1078-0432.CCR-14-0742.DC1

Cited articles
This article cites 43 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/19/5052.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/20/19/5052.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.